Mantle cell lymphoma

From Libre Pathology
Jump to navigation Jump to search

Mantle cell lymphoma, abbreviated MCL, is less common small cell lymphoma that is relatively aggressive when compared to other small cell lymphomas.

Mantle cell lymphoma
Diagnosis in short

Mantle cell lymphoma. H&E stain.
LM small monomorphic (uniform size, shape and staining) lymphoid population with abundant mitoses, +/-scattered epithelioid histiocytes (should not be confused with tingible-body macrophages), +/-sclerosed blood vessels
Subtypes blastic variant
LM DDx other small cell lymphomas (esp. MALT lymphoma), Burkitt lymphoma
IHC cyclin D1 +ve, CD5 +ve, CD43 +ve, CD20 +ve, CD23 -ve
Molecular t(11;14)(q13;q32) / IGH-CCND1
Site lymph node, GI tract, other sites
Prevalence not common
Prognosis moderately aggressive to poor

General

  • Relatively aggressive - guarded prognosis.[1]
  • Rare ~ 2% of non-Hogkin's lymphoma in a series of over 4000 patients.[2]

GI tract - typically:[3]

  • Abdominal pain (~37% of cases) or GI bleeding (~26% of cases).

Gross

  • GI tract: polypoid lesions (~50% of cases).[3]

Microscopic

Features:[4]

  • Typically a small monomorphic (uniform size, shape and staining) lymphoid population.
    • May be "large" (blastic variant of mantle cell lymphoma) with 1 or 2 nucleoli.[5]
  • Abundant mitoses.
  • Scattered epithelioid histiocytes (should not be confused with tingible-body macrophages).
  • Sclerosed blood vessels.

DDx:

Images

  • MCL - low mag. (WC)

  • MCL - intermed. mag. (WC)

  • MCL - low mag. - cyclin D1. (WC)

  • MCL - intermed. mag. - cyclin D1. (WC)

www:

IHC

  • CD45 +ve.
  • CD20 +ve.
  • CD79a +ve.
  • CD5 +ve -- important.
    • Negative in case reports.[7]
  • CD43 +ve.
  • Cyclin D1 +ve -- key immunostain.

Others:

  • CD23 -ve.
    • Positive in CLL.

Molecular

  • t(11;14)(q13;q32) / IGH-CCND1.[9]

Sign out

TERMINAL ILEUM, BIOPSY:
- MANTLE CELL LYMPHOMA.

COMMENT:
The tumour consists of small lymphoid cells in sheets.

The tumour stains as follows:
POSITIVE: CD20, CD5, BCL2, cyclin D1.
NEGATIVE: CD23, BCL6, CD10.
PROLIFERATION (Ki-67): 25%.

See also

References

  1. ↑ Hankin, RC.; Hunter, SV. (Dec 1999). "Mantle cell lymphoma.". Arch Pathol Lab Med 123 (12): 1182-8. doi:10.1043/0003-9985(1999)1231182:MCL2.0.CO;2. PMID 10583923.
  2. ↑ Gujral S, Agarwal A, Gota V, et al. (2008). "A clinicopathologic study of mantle cell lymphoma in a single center study in India". Indian J Pathol Microbiol 51 (3): 315–22. PMID 18723950.
  3. ↑ 3.0 3.1 Kim, JH.; Jung, HW.; Kang, KJ.; Min, BH.; Lee, JH.; Chang, DK.; Kim, YH.; Son, HJ. et al. (2012). "Endoscopic findings in mantle cell lymphoma with gastrointestinal tract involvement.". Acta Haematol 127 (3): 129-34. doi:10.1159/000333139. PMID 22236942.
  4. ↑ Good, D. 17 August 2010.
  5. ↑ Todorovic M, Pavlovic M, Balint B, et al. (2007). "Immunophenotypic profile and clinical characteristics in patients with advanced stage mantle cell lymphoma". Med. Oncol. 24 (4): 413–8. PMID 17917091.
  6. ↑ Bernard M, Gressin R, Lefrère F, et al. (November 2001). "Blastic variant of mantle cell lymphoma: a rare but highly aggressive subtype". Leukemia 15 (11): 1785–91. PMID 11681422.
  7. ↑ URL: http://path.upmc.edu/cases/case308/dx.html. Accessed on: 14 January 2012.
  8. ↑ Online 'Mendelian Inheritance in Man' (OMIM) 168461
  9. ↑ URL: http://atlasgeneticsoncology.org/Anomalies/t1114ID2021.html. Accessed on: 10 August 2010.
Retrieved from "https://librepathology.org/w/index.php?title=Mantle_cell_lymphoma&oldid=31662"